Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245765 | 1.00 | MMP8 (0.59) | MMP8CYP1A2CYP2C9HIF1AALDH1A1 | |
| SCHEMBL1785293 | 1.00 | MMP8 (0.59) | MMP8CYP1A2CYP2C9HIF1AALDH1A1 | |
| SCHEMBL5390701 | 0.93 | MMP8 (0.54) | MMP8CYP1A2CYP2C9HIF1AALDH1A1 | |
| SCHEMBL5375675 | 0.87 | L3MBTL1 (0.65) | ALDH1A1PPARGL3MBTL1LMNA | |
| SCHEMBL1596779 | 0.87 | L3MBTL1 (0.65) | ALDH1A1PPARGL3MBTL1LMNA | |
| SCHEMBL4756342 | 0.87 | L3MBTL1 (0.65) | ALDH1A1PPARGL3MBTL1LMNA | |
| SCHEMBL5810826 | 0.86 | LMNA (0.51) | MMP8CYP1A2ALDH1A1PPARGNPC1 | |
| SCHEMBL14305548 | 0.85 | NPY1R (0.56) | MMP8CYP1A2CYP2C9HIF1AALDH1A1 | |
| SCHEMBL5385979 | 0.84 | ESR1 (0.50) | MMP8CYP1A2CYP2C9HIF1A | |
| SCHEMBL5100527 | 0.84 | ESR1 (0.50) | MMP8CYP1A2CYP2C9HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137497-B | Bicyclic derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-06-15 | — | — | CN | disclosed |
| WO-2021067827-A1 | MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-10449208-B2 | Antiviral prodrugs of tenofovir | MERCK SHARP & DOHME CORP. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20140031230-A1 | AUXIN BIOSYNTHESIS INHIBITOR | Riken Public University Corporation Yokohama City University | 2014-01-30 | — | — | US | disclosed |
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
| EP-0417698-B1 | Amino acid derivatives having renin-inhibiting activity, process for their preparation, agents containing them, and their use | HOECHST AG (DE) | 1996-03-13 | — | — | EP | disclosed |
| US-5374731-A | Treatment of high blood pressure, congestive heart failure and viral disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-12-20 | — | — | US | disclosed |
| EP-0417698-A2 | Amino acid derivatives having renin-inhibiting activity, process for their preparation, agents containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | MMP8 3352/4885CYP1A2 2824/4885CYP2C9 3509/4885 |
| US-10449208-B2 | Antiviral prodrugs of tenofovir | PNP, TYMP, HPRT1 | MMP8 681/4885CYP1A2 800/4885CYP2C9 130/4885 |
| US-20140031230-A1 | AUXIN BIOSYNTHESIS INHIBITOR | AGXT, AOX1, FDPS | MMP8 4444/4885CYP1A2 356/4885CYP2C9 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.